论文部分内容阅读
目的:分析临床过敏性紫癜肾早期损害患者行低分子肝素钙治疗的效果。方法:将本院于2012年5月-2015年4月自愿参与调查的过敏性紫癜肾早期损害患者80例作为观察对象,按意愿分成不同临床处理组,即:对照组(予开瑞坦、葡萄糖酸钙治疗)、观察组(于对照组基础上加用低分子肝素钙),比较两组患者疾病预后评估效果。结果:观察组患者预后尿微量白蛋白、尿β2-微球蛋白、尿免疫球蛋白G等指标变化程度优于对照组(P<0.05)。结论:临床针对过敏性紫癜肾早期损害患者行低分子肝素钙疗法作用显著,可延缓病情发展,减少不良反应发生。
Objective: To analyze the effect of low molecular weight heparin calcium treatment in patients with clinically anaphylactoid purpura nephropathy. Methods: Eighty patients with Henoch-Schonlein purpura who were voluntarily involved in the survey from May 2012 to April 2015 in our hospital were divided into different clinical treatment groups according to their willingness, namely: control group (preeclagestone, glucose Calcium treatment), the observation group (on the basis of the control group plus low molecular weight heparin), the prognosis of the two groups were compared. Results: The changes of urinary albumin, urine β2-microglobulin and urinary immunoglobulin G in the observation group were better than those in the control group (P <0.05). Conclusion: The clinical treatment of Alzheimer ’s disease in patients with early renal damage of low molecular weight heparin calcium therapy significantly delayed the progression of the disease and reduce adverse reactions.